Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients

医学 内科学 人口 免疫性血小板减少症 队列 儿科 外科 血小板 环境卫生
作者
Francesca Palandri,Cristina Santoro,Monica Carpenedo,Silvia Cantoni,Wilma Barcellini,Giuseppe Carli,Valentina Carrai,Elena Rossi,Elena Rivolti,Alessandro Lucchesi,Francesco Rotondo,Giuseppe Auteri,Marco Ruggeri,Alessio Fusco,Erminia Baldacci,Lucia Catani,Daniela Bartoletti,Michèle Cavo,Valerio De Stefano,Maria Gabriella Mazzucconi
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 2433-2433
标识
DOI:10.1182/blood-2018-99-114586
摘要

Abstract Introduction . Elderly patients (pts) with Immune thrombocytopenia (ITP) may represent a clinical challenge since comorbidities and impaired functional capacity may reduce the therapeutic landscape and drug tolerability. Aims . To report ITP characteristics at diagnosis, and type/timing of treatment strategy, including response and toxicity rates in a cohort of elderly ITP pts. Methods. An electronic database was established to retrospectively collect clinical/laboratory data on elderly (age ≥60 yrs) pts that received at least one line of therapy for ITP in 11 Italian Hematology Centers. Data cut-off was July 2018. Treatment decisions were at the physician's discretion. Diagnosis and responses were assessed according to current guidelines and terminology. Infectious, thrombotic and hemorrhagic complications were graded according to the WHO scale. Comparisons of quantitative variables between groups were carried out by Wilcoxon-Mann-Whitney rank-sum test, and association between categorical variables (2-way tables) was tested by χ2 test. Cumulative incidences of infections, bleeding, and thrombosis were calculated considering death as competing risk (Fine and Gray model). Statistical significance was set at p<0.05. Results. Between January 1981 and January 2018, 526 ITP pts were diagnosed and treated in participating Centers. Median follow-up was 4.2 yrs (range: 0.25-24.4 yrs). Baseline characteristics of the total population were: median age 71.3 yrs (60-91.5); median platelet count 16 (1-99); number of pts with hemorrhages 134 (25.5%, grade 3-4: 6.3%). All pts received a front-line therapy that was mainly based on prednisone (dexamethasone was used in 13.1% of the pts, regardless of age). Therapy was started at the time of diagnosis or in chronic phase in 75% and 16.9% of the cases, respectively; 94 pts (17.9%) had no response. A second-line approach was required in 334 pts (63.5%) while 173 (32.9%) patients received also a third-line therapy; 76 (14.4%) pts required ≥4 treatment therapies. Eighty-four (16%) pts died; death was due to major hemorrhage in 9 pts, to thrombosis in 8 pts and to infection in 9 pts. A total of 54 thromboses in 50 pts, 201 bleedings in 136 pts and 133 infections in 108 pts were observed during follow-up. Incidence rate of all-grade and ≥ grade-3 complications were: 4.60 and 1.15 per 100 pt-yrs (hemorrhages); 1.69 and 1.12 per 100 pt-yrs (thrombosis); 3.65 and 0.74 per 100 pt-yrs (infections). Pts were sub-grouped into two categories according to age (elderly: 60-74 yrs, n.315, 59.9%; very elderly: ≥75 yrs, n.211, 40.1%). At diagnosis, bone marrow biopsy was performed more frequently in pts <75 yrs (68.5% vs 56.8% in the very elderly, p=0.007). Compared to elderly pts, very elderly had similar platelet count at diagnosis but presented more frequently with cardiovascular risk factors (83.4% vs 63.8%, p<0.001) and were more frequently treated with anticoagulants (15.6% vs 4.1%, p<0.001), resulting in a higher rate of bleedings at diagnosis (32.2% vs 21.3%, p=0.005). The type of front-line treatment was comparable across age groups (Figure 1A). Intensity (duration and dose) of prednisone treatment was not influenced by age, resulting in comparable response rates (16.5% and 14.7% of no-responders in elderly/very elderly pts, respectively; p=0.18). Second-line, rituximab and splenectomy were most frequently used in pts aged <75, while very elderly received more frequently thrombopoietin-receptor agonists (TPO-ra) (Figure 1B). Third-line, splenectomy was reserved to patients aged <75, while the use of medical therapy was comparable across age groups (Figure 1C). After adjustment for the risk of death, the cumulative incidence of bleedings, thromboses and infections was significantly higher in the very elderly (p=0.004, p=0.001 and p=0.01) (Figure 2). Conclusions. Very elderly pts were characterized by a higher frequency and severity of comorbidities and a higher need of chronic anticoagulant therapy, resulting in a more aggressive disease presentation. While first-line corticosteroid therapy was not influenced by age, very elderly pts were excluded from the use of splenectomy and exposed to an earlier use of TPO-ra. Overall, older age identified a more fragile population with a more severe disease course, in terms of hemorrhagic, thrombotic and infectious complications. Age-adapted treatment strategies should be further explored in elderly ITP pts. Disclosures Palandri: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Cavo:AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mazzucconi:Baxalta-Shire: Consultancy, Speakers Bureau; Bayer: Consultancy, Speakers Bureau; Novartis,: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Novo Nordisk: Consultancy, Speakers Bureau; CSL Behring: Consultancy, Speakers Bureau. Rodeghiero:Amgen, Novartis, Argenx: Consultancy, Honoraria, Speakers Bureau.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_李开心完成签到,获得积分10
刚刚
小白板完成签到,获得积分10
1秒前
所所的应助被凶狠的乌龟采纳,获得10
1秒前
1秒前
烟花的应助被何雨航采纳,获得10
2秒前
健康的饼干完成签到,获得积分10
2秒前
2秒前
香蕉觅云的应助被油菜的星星采纳,获得10
2秒前
北海发布了新的文献求助10
2秒前
王哈哈发布了新的文献求助10
2秒前
慕青的应助被zq采纳,获得10
3秒前
情怀的应助被细心小鸽子采纳,获得10
3秒前
Eva完成签到,获得积分10
3秒前
河洛之神完成签到,获得积分10
4秒前
4秒前
谷策完成签到,获得积分10
4秒前
5秒前
kkkkkkk完成签到,获得积分10
5秒前
5秒前
111完成签到,获得积分10
5秒前
一一完成签到,获得积分20
6秒前
风车车发布了新的文献求助20
7秒前
研友_VZG7GZ的应助被受伤白安采纳,获得10
7秒前
7秒前
Maple完成签到,获得积分10
7秒前
杨雨洁完成签到,获得积分10
8秒前
bkagyin的应助被研友_李开心采纳,获得10
8秒前
NexusExplorer的应助被阿希本希呀采纳,获得30
8秒前
lll完成签到,获得积分10
8秒前
bkagyin的应助被Demon采纳,获得10
9秒前
童宝完成签到,获得积分10
9秒前
9秒前
豆本豆发布了新的文献求助10
10秒前
11秒前
11秒前
12秒前
JJ完成签到 ,获得积分10
12秒前
科研通AI6.4的应助被感动苡采纳,获得10
13秒前
勤奋雨发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182352
求助须知:如何正确求助?哪些是违规求助? 9571930
关于积分的说明 21820825
捐赠科研通 7778861
什么是DOI,文献DOI怎么找? 3433657
关于科研通互助平台的介绍 2557824
邀请新用户注册赠送积分活动 2479703